Christopher Leamon
Company: Fusion Pharmaceuticals
Job title: Chief Scientific Officer
Seminars:
Chair’s Opening Remarks 8:20 am
day: Conference Day Two
Panel Discussion: Obstacles & Opportunities in the Pricing & Reimbursement of Radiopharmaceuticals Across European Countries – Comparing UK, France & Germany 9:00 am
day: Conference Day Two
Advancing Fusion’s Targeted 225 Ac Platform- A Glimpse at What’s Clinically Advancing & What’s to Follow post the Astra Zeneca Acquisition 9:00 am
Outlining why 225Ac remains an attractive radioisotope for targeted therapy Uncovering strategies for antibody-based radiotherapy Navigating clinical strategy and updates on Fusion’s antibody and small molecule programs, including FPI-2265 (phase 2/3 study)Read more
day: Conference Day One